Gene therapy Archives

News and Trends 12 Jan 2023

Team wins $149M contract for National Institute of Neurological Disorders and Stroke

A team consisting of Battelle, AmplifyBio and Andelyn Biosciences has won a seat on an eight-year, $149 million indefinite delivery, indefinite quantity (IDIQ) contract vehicle for the National Institute of…

January 12, 2023 - 3 minutesmins - By Jim Cornall

Woman looking through a window and seeing biotechnology such as pills and vaccines. It indicates the biotech trends coming in the future

Best in Biotech 12 Jan 2023

The biggest biotech trends that will shape 2023

2023 has begun at full throttle. We have collected seven major biotech trends that industry experts are keeping an eye on over the next 12 months. Just like that, another…

January 12, 2023 - 9 minutesmins - By Jonathan Smith

News and Trends 11 Jan 2023

Clinical trends for 2023

By Richard Staines, account director, Optimum Strategic Communications Few would deny that the decade has had a turbulent start, but after the tragedies of the COVID-19 pandemic and the Ukraine…

January 11, 2023 - 8 minutesmins - By External Contributor

Advanced Therapies Week: Advancing the next pillar in medicine

Advanced Therapies Week (ATW) by Phacilitate is the premiere venue to partner in the cell and gene therapies space. Join thousands of biotechs, pharmas, investors, ln-licensors, academics and suppliers for a…

January 10, 2023 - 2 minutesmins - By External Contributor

News and Trends 9 Jan 2023

Selecta and Astellas sign LOPD treatment agreement

Selecta Biosciences, Inc. and Astellas Pharma Inc. have announced an exclusive licensing and development agreement for IdeXork (Xork). Xork is being studied as a potential next generation immunoglobulin G (IgG)…

January 9, 2023 - 3 minutesmins - By Jim Cornall

News and Trends 5 Jan 2023

2023 Editorial Calendar updated

Each month here at Labiotech.eu, we produce a special newsletter. While still news-related, these special editions are an opportunity to take a deeper look at topics of interest. It also…

January 5, 2023 - 3 minutesmins - By Jim Cornall

News and Trends 20 Dec 2022

Ori Biotech and Inceptor Bio partner on solid tumor cell therapy

Cell and gene therapy (CGT) company Ori Biotech, and cell therapy firm Inceptor Bio have announced a new partnership. The deal will utilize Ori Biotech’s manufacturing platform technology to support…

December 20, 2022 - 2 minutesmins - By Jim Cornall

News and Trends 16 Dec 2022

Beyond Biotech podcast 26: CellCentric, MicrofluidX, Potter Clarkson

This week, we have three guests. We have conversations with Antoine Espinet, CEO of MicrofluidX; Will West, CEO of CellCentric; and Sara Holland, patent attorney at Potter Clarkson. MicrofluidX raises…

December 16, 2022 - 5 minutesmins - By Jim Cornall

News and Trends 16 Dec 2022

CSL closer to gene therapy treatments for hemophilia B patients in Europe

CSL says the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending conditional marketing authorization (CMA) of etranacogene dezaparvovec. Etranacogene dezaparvovec…

December 16, 2022 - 2 minutesmins - By Jim Cornall

In Depth 15 Dec 2022

To avoid stagnation, the EU must refine its ATMP regulation

Over the decades, the EU has spearheaded the adoption of advanced therapy medicinal products (ATMPs) such as cell and gene therapies. However, changes are needed to ATMP regulations to keep…

December 15, 2022 - 8 minutesmins - By Jonathan Smith

News and Trends 15 Dec 2022

EMA gives Myrtelle’s Canavan disease gene therapy candidate OD designation

Myrtelle Inc., a clinical stage gene therapy company, has announced that the European Medicines Agency (EMA) has granted orphan drug (OD) designation for rAAV-Olig001-ASPA, the company’s lead gene therapy product…

December 15, 2022 - 3 minutesmins - By Jim Cornall

News and Trends 14 Dec 2022

Replay targets genetic brain disorders with new gene therapy company, Kaleibe

Replay, a genome writing company, today announced the launch of Kaleibe, an HSV gene therapy company targeting genetic brain disorders. It is the third of Replay’s product companies to launch…

December 14, 2022 - 4 minutesmins - By Jim Cornall

News and Trends 8 Dec 2022

MicrofluidX raises £3.3M to develop advanced therapy manufacturing platform

MicrofluidX (MFX), a U.K. based provider of next-generation bioreactors for cell research and manufacturing, has announced £3.3 million ($4 million) of secured investments. This brings the company’s total funding to…

December 8, 2022 - 2 minutesmins - By Jim Cornall

News and Trends 8 Dec 2022

Polyplus announces completion of acquisition of Xpress Biologics to expand plasmid DNA

Polyplus has announced the completion of an acquisition of Belgian Xpress Biologics to expand plasmid DNA technology. Xpress Biologics specializes in the production of plasmid DNA and protein using microbial…

December 8, 2022 - 2 minutesmins - By Liza Laws

News and Trends 5 Dec 2022

MaxCyte and Curamys sign cell and gene therapies agreement

MaxCyte, Inc. and Curamys have announced the signing of a strategic platform license. MaxCyte is a cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization…

December 5, 2022 - 2 minutesmins - By Jim Cornall

News and Trends 1 Dec 2022

FDA clears SparingVision’s investigational new drug application to treat ocular diseases

SparingVision today announces that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug application (IND) for SPVN06. The genomic medicine company has had its developing vision-saving…

December 1, 2022 - 4 minutesmins - By Liza Laws

More News! 30 Nov 2022

FDA grants Sensorion Orphan Drug Designation for hearing loss drug

Sensorion a clinical-stage biotechnology company has announced that the US Food and Drug Administration (FDA) has granted orphan drug designation (ODD) to OTOF-GT, its lead gene therapy program. The drug…

November 30, 2022 - 3 minutesmins - By Liza Laws

News and Trends 29 Nov 2022

BioPharma Dynamics expands to provide more solutions for cell and gene therapy industry

BioPharma Dynamics have expanded their portfolio for the cell and gene therapy market to offer a range of chemically defined T-Cell media, DMSO-free cryopreservation solutions, and recombinant growth factors. Suitable…

November 29, 2022 - 2 minutesmins - By Liza Laws

Miquel Vila Perelló gene therapy SpliceBio

Interview 28 Nov 2022

Breaking barriers to gene therapies for childhood rare diseases

The majority of known rare genetic diseases affect children, and gene therapies could help them live normal lives. Miquel Vila-Perelló, CEO and co-founder of the Spanish biotech SpliceBio, outlines how…

November 28, 2022 - 5 minutesmins - By Jonathan Smith

News and Trends 24 Nov 2022

Gene therapy approval “game changer” in hemophilia B treatment

The approval of CSL's gene therapy Hemgenix has ushered in a new era for hemophilia B treatment. With the addition of other approvals like Rocktavian and Upstaza, 2022 could be…

November 24, 2022 - 7 minutesmins - By Jonathan Smith

Report: new Frontiers in Vaccinology

Listen to our podcast

View all sectors A-Z

The Biotech Perspective 2023

View all companies A-Z

Find new scientific partnerships. Create a free IN-PART account

View all countries A-Z

Report: The European Biotech Startup Ecosystem

Subcribe to our newsletter

Learn more about Inova, the leading platform for biopharma partnering